Literature DB >> 28139757

Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy.

J V Hegde1, D J Margolis2, P-C Wang1, R E Reiter3, J Huang4, M L Steinberg1, M Kamrava1.   

Abstract

BACKGROUND: In focused radiotherapy for prostate cancer (PC), a full dose of radiation is delivered to the index lesion while reduced dose is delivered to the remaining prostate to reduce morbidity. As PC is commonly multifocal, we investigated whether baseline clinical characteristics or multiparametric magnetic resonance imaging (mpMRI) may be useful to predict the actual pathologic distribution of PC in men with intermediate- or high-risk PC, which may better inform how to deliver focused radiotherapy.
METHODS: A retrospective single-institutional study was performed on 71 consecutive men with clinically localized, intermediate- or high-risk PC who underwent mpMRI followed by radical prostatectomy (RP) from January 2012 to December 2012. Logistic regression analysis was performed to evaluate preoperative predictors for satellite lesions. Performance characteristics of mpMRI to detect satellite lesions and the extent of prostate disease (one hemi-gland vs both) were also evaluated.
RESULTS: In all, 50.7% had satellite lesions on mpMRI. On RP specimen analysis, 66.2% had satellite lesions and 55.3% of these satellite lesions had pathologic Gleason score (pGS)⩾3+4. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy for mpMRI detecting a satellite lesion being present in the RP specimen were 59.6%, 66.7%, 77.8%, 45.7% and 62.0%, respectively. The presence of MRI satellite lesions was the only preoperative predictor significantly associated with finding satellite lesions on final pathology (hazard ratio (HR), 2.95, P=0.040). There was agreement in 76.1% of the entire cohort for unilateral vs bilateral disease when incorporating both biopsy and mpMRI information and comparing with the RP specimen.
CONCLUSIONS: In intermediate risk or greater PC, only the presence of mpMRI satellite lesions could predict for pathologic satellite lesions. While combining biopsy and mpMRI information may improve preoperative disease localization, the relatively high incidence of bilateral hemi-gland involvement with pGS ⩾7 satellite lesions makes it challenging to appropriately select men eligible for hemi-gland therapy.

Entities:  

Mesh:

Year:  2017        PMID: 28139757      PMCID: PMC6946385          DOI: 10.1038/pcan.2016.75

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  24 in total

1.  Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial.

Authors:  Alfonso Gomez-Iturriaga; Francisco Casquero; Arantza Urresola; Ana Ezquerro; Jose I Lopez; Jose M Espinosa; Pablo Minguez; Roberto Llarena; Ana Irasarri; Pedro Bilbao; Juanita Crook
Journal:  Radiother Oncol       Date:  2016-02-15       Impact factor: 6.280

2.  Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology.

Authors:  Jesse D Le; Nelly Tan; Eugene Shkolyar; David Y Lu; Lorna Kwan; Leonard S Marks; Jiaoti Huang; Daniel J A Margolis; Steven S Raman; Robert E Reiter
Journal:  Eur Urol       Date:  2014-09-23       Impact factor: 20.096

3.  Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology.

Authors:  Nelly Tan; Daniel J Margolis; David Y Lu; Kevin G King; Jiaoti Huang; Robert E Reiter; Steven S Raman
Journal:  AJR Am J Roentgenol       Date:  2015-07       Impact factor: 3.959

4.  Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy.

Authors:  M Karavitakis; M Winkler; P Abel; N Livni; I Beckley; H U Ahmed
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-05-25       Impact factor: 5.554

5.  Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.

Authors:  Andrea Gallina; Carmen Maccagnano; Nazareno Suardi; Umberto Capitanio; Firas Abdollah; Marco Raber; Andrea Salonia; Vincenzo Scattoni; Patrizio Rigatti; Francesco Montorsi; Alberto Briganti
Journal:  BJU Int       Date:  2011-11-17       Impact factor: 5.588

Review 6.  Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?

Authors:  Olivier Wegelin; Harm H E van Melick; Lotty Hooft; J L H Ruud Bosch; Hans B Reitsma; Jelle O Barentsz; Diederik M Somford
Journal:  Eur Urol       Date:  2016-08-25       Impact factor: 20.096

7.  Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.

Authors:  Thomas J Polascik; Janice M Mayes; Florian R Schroeck; Leon Sun; John F Madden; Judd W Moul; Vladimir Mouraviev
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

8.  Parameters predicting postoperative unilateral disease in patients with unilateral prostate cancer in diagnostic biopsy: a rationale for selecting hemiablative focal therapy candidates.

Authors:  Stavros Sfoungaristos; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

9.  Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers.

Authors:  Masanori Noguchi; Thomas A Stamey; John E McNeal; Rosalie Nolley
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

10.  Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens.

Authors:  Alphaeus M Wise; Thomas A Stamey; John E McNeal; John L Clayton
Journal:  Urology       Date:  2002-08       Impact factor: 2.649

View more
  1 in total

Review 1.  Ablative options for prostate cancer management.

Authors:  Rafael R Tourinho-Barbosa; Lucas Teixeira Batista; Xavier Cathelineau; Javier Sanchez-Macias; Rafael Sanchez-Salas
Journal:  Turk J Urol       Date:  2020-10-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.